{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:04:32Z","timestamp":1795111472553,"version":"4.10.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI179699"],"award-info":[{"award-number":["UM1 AI179699"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08973-w","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T13:24:20Z","timestamp":1755264260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-0865","authenticated-orcid":false,"given":"Linda J.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo E.","family":"Vel\u00e1squez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Kempker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie Z.","family":"Imperial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nuermberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ignatius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janeway","family":"Granche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P. J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Furin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunsol","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Chiambah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Van Grack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhoanna","family":"Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Shenje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Nerette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Kanyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Bakyayita","family":"Kyeyune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mendoza-Ticona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Murtaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Foraida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Goth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"10","key":"8973_CR1","first-page":"S231","volume":"3","author":"W Fox","year":"1999","unstructured":"Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231\u201379.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"Supplement 36","key":"8973_CR2","doi-asserted-by":"publisher","first-page":"87S","DOI":"10.1183\/09031936.02.00309102","volume":"20","author":"MD Iseman","year":"2002","unstructured":"Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J. 2002Jul 1;20(Supplement 36):87S \u2013 94s.","journal-title":"Eur Respir J"},{"key":"8973_CR3","doi-asserted-by":"crossref","unstructured":"Murray JF, Schraufnagel DE, Hopewell PC. Treatment of Tuberculosis. A Historical Perspective. Ann Am Thorac Soc. 2015 Dec;12(12):1749\u201359.","DOI":"10.1513\/AnnalsATS.201509-632PS"},{"key":"8973_CR4","unstructured":"WHO. WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-susceptible tuberculosis treatment. [Internet]. 2022 [cited 2024 Apr 16]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240048126."},{"key":"8973_CR5","unstructured":"World Health Organization. Target regimen profiles for tuberculosis treatment, 2023 update. World Health Organization; 2023."},{"key":"8973_CR6","unstructured":"CDC. 2021 State and City TB Report [Internet]. [cited 2024 Apr 16]. Available from: https:\/\/www.cdc.gov\/tb\/statistics\/indicators\/2021\/completionTherapy.htm."},{"issue":"11","key":"8973_CR7","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","volume":"24","author":"MZ Imperial","year":"2018","unstructured":"Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708\u201315.","journal-title":"Nat Med"},{"key":"8973_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209333.262","author":"C Tweed","year":"2016","unstructured":"Tweed C, Wills G, Crook A, Meredith S, Nunn A, Mendel C, et al. P119 using adverse events in a tuberculosis trial to describe the tolerability of standard therapy. Thorax. 2016. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-209333.262.","journal-title":"Thorax"},{"issue":"7","key":"8973_CR9","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147\u201395.","journal-title":"Clin Infect Dis"},{"key":"8973_CR10","unstructured":"CDC. Core Curriculum on Tuberculosis: What the Clinician Should Know [Internet]. [cited 2024 Jul 17]. Available from: https:\/\/www.cdc.gov\/tb\/media\/Core_Curriculum_TB_eBook.pdf."},{"key":"8973_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","volume":"53","author":"M Regazzi","year":"2014","unstructured":"Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug\u2013drug interactions with rifamycins. Clin Pharmacokinet. 2014;53:489\u2013507.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"8973_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/FTD.0000000000000108","volume":"37","author":"HH Semvua","year":"2015","unstructured":"Semvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther Drug Monit. 2015;37(1):22\u201332.","journal-title":"Ther Drug Monit"},{"key":"8973_CR13","unstructured":"Stop TB Partnership. Global Plan to End TB: A blueprint of priority actions and estimate of financial resources needed to end TB [Internet]. [cited 2024 May 28]. Available from: https:\/\/www.stoptb.org\/global-plan-to-end-tb\/global-plan-to-end-tb-2023-2030."},{"key":"8973_CR14","unstructured":"US Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs [Internet]. [cited 2024 Jul 22]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs."},{"issue":"10","key":"8973_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020M;382(10):893\u2013902.","journal-title":"N Engl J Med"},{"issue":"9","key":"8973_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022S;387(9):810\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"8973_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1128\/AAC.01691-15","volume":"60","author":"R Tasneen","year":"2016","unstructured":"Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, et al. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother. 2016Jan;60(1):270\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"8973_CR18","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1128\/AAC.00384-12","volume":"56","author":"K Williams","year":"2012","unstructured":"Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, et al. Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2012Jun;56(6):3114\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"8973_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","volume":"180","author":"KN Williams","year":"2009","unstructured":"Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, et al. Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis. Am J Respir Crit Care Med. 2009Aug 15;180(4):371\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"8973_CR20","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1128\/AAC.01182-08","volume":"53","author":"KN Williams","year":"2009","unstructured":"Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, et al. Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model. Antimicrob Agents Chemother. 2009Apr;53(4):1314\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"8973_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1056\/NEJMc2119461","volume":"387","author":"ND Goswami","year":"2022","unstructured":"Goswami ND, Ashkin D, Haley CA. Pretomanid in the treatment of patients with tuberculosis in the United States. N Engl J Med. 2022;387(9):850\u20132.","journal-title":"N Engl J Med"},{"issue":"7","key":"8973_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/cid\/ciad312","volume":"77","author":"CA Haley","year":"2023","unstructured":"Haley CA, Schechter MC, Ashkin D, Peloquin CA, Peter Cegielski J, Andrino BB, et al. Implementation of bedaquiline, pretomanid, and linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant tuberculosis disease. Clin Infect Dis. 2023;77(7):1053\u201362.","journal-title":"Clin Infect Dis"},{"key":"8973_CR23","doi-asserted-by":"crossref","unstructured":"Cheng N, Wu S, Luo X, Xu C, Lou Q, Zhu J, et al. A comparative study of chest computed tomography findings: 1030 cases of drug-sensitive tuberculosis versus 516 cases of drug-resistant tuberculosis. Infect Drug Resist. 2021;1115\u201328.","DOI":"10.2147\/IDR.S300754"},{"issue":"6","key":"8973_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176354","volume":"12","author":"D Li","year":"2017","unstructured":"Li D, He W, Chen B, Lv P. Primary multidrug-resistant tuberculosis versus drug-sensitive tuberculosis in non-HIV-infected patients: comparisons of CT findings. PLoS One. 2017;12(6): e0176354.","journal-title":"PLoS One"},{"key":"8973_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.612675","volume":"12","author":"A Allu\u00e9-Guardia","year":"2021","unstructured":"Allu\u00e9-Guardia A, Garc\u00eda JI, Torrelles JB. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol. 2021;12: 612675.","journal-title":"Front Microbiol"},{"issue":"7","key":"8973_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.5588\/ijtld.14.0868","volume":"19","author":"R Dawson","year":"2015","unstructured":"Dawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Efron A, et al. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2015;19(7):780\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"8973_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5588\/ijtld.20.0513","volume":"25","author":"C Tweed","year":"2021","unstructured":"Tweed C, Wills G, Crook A, Amukoye E, Balanag V, Ban A, et al. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. Int J Tuberc Lung Dis. 2021;25(4):305\u201314.","journal-title":"Int J Tuberc Lung Dis"},{"key":"8973_CR28","unstructured":"ClinicalTrials.gov. A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults [Internet]. [cited 2024 Jul 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03758612."},{"issue":"1","key":"8973_CR29","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.1038\/s41467-024-50781-4","volume":"15","author":"N Strydom","year":"2024","unstructured":"Strydom N, Ernest JP, Imperial M, Solans BP, Wang Q, Tasneen R, et al. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. Nat Commun. 2024Aug 25;15(1):7311.","journal-title":"Nat Commun"},{"issue":"4","key":"8973_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00035-23","volume":"67","author":"SY Li","year":"2023","unstructured":"Li SY, Converse PJ, Betoudji F, Lee J, Mdluli K, Upton A, et al. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model. Antimicrob Agents Chemother. 2023Apr 18;67(4): e0003523.","journal-title":"Antimicrob Agents Chemother"},{"key":"8973_CR31","doi-asserted-by":"crossref","unstructured":"Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, et al. Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis. Pett SL, editor. PLoS ONE. 2014 Apr 14;9(4):e94462.","DOI":"10.1371\/journal.pone.0094462"},{"issue":"2","key":"8973_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1128\/AAC.01179-10","volume":"55","author":"RS Wallis","year":"2011","unstructured":"Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, et al. Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis. Antimicrob Agents Chemother. 2011Feb;55(2):567\u201374.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"8973_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/655471","volume":"202","author":"RS Wallis","year":"2010","unstructured":"Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, et al. Pharmacokinetics and Whole-Blood Bactericidal Activity against Mycobacterium tuberculosis of Single Doses of PNU-100480 in Healthy Volunteers. J Infect Dis. 2010Sep;202(5):745\u201351.","journal-title":"J Infect Dis"},{"key":"8973_CR34","doi-asserted-by":"publisher","unstructured":"Heinrich N, Manyama C, Koele SE, Mpagama S, Mhimbira F, Sebe M, Wallis RS, Ntinginya N, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Stoycheva K, Zumba T, Nore\u00f1a I, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut J, Aarnoutse RE, McHugh TD, Wildner L, Boeree M, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM; PanACEA consortium. Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial. Lancet Infect Dis. 2025:S1473-3099(25)00213-0. https:\/\/doi.org\/10.1016\/S1473-3099(25)00213-0. Epub ahead of print. PMID: 40645196.","DOI":"10.1016\/S1473-3099(25)00213-0"},{"issue":"4","key":"8973_CR35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ccm.2019.08.001","volume":"40","author":"EH Ignatius","year":"2019","unstructured":"Ignatius EH, Dooley KE. New Drugs for the Treatment of Tuberculosis. Clin Chest Med. 2019Dec;40(4):811\u201327.","journal-title":"Clin Chest Med"},{"key":"8973_CR36","unstructured":"Working Group on New TB Drugs. 2024 Global New TB Drug Pipeline [Internet]. [cited 2024 Apr 16]. Available from: https:\/\/www.newtbdrugs.org\/pipeline\/clinical."},{"key":"8973_CR37","unstructured":"ClinicalTrials.gov. Short-course Regimens for the Treatment of Pulmonary Tuberculosis (CRUSH-TB) [Internet]. [cited 2024 Apr 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05766267."},{"key":"8973_CR38","unstructured":"ClinicalTrials.gov. Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis [Internet]. [cited 2024 Apr 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05971602."},{"key":"8973_CR39","unstructured":"ClinicalTrials.gov. PanACEA - STEP2C -01 [Internet]. [cited 2024 Apr 16]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05807399."},{"issue":"11","key":"8973_CR40","doi-asserted-by":"publisher","first-page":"886","DOI":"10.5588\/ijtld.21.0515","volume":"25","author":"MJ Boeree","year":"2021","unstructured":"Boeree MJ, Lange C, Thwaites G, Paton N, De Vrueh R, Barros D, et al. UNITE4TB: A new consortium for clinical drug and regimen development for TB. Int J Tuberc Lung Dis. 2021Nov 1;25(11):886\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"8973_CR41","unstructured":"ACTG. Advancing Clinical Therapeutics Globally (ACTG) for HIV\/AIDS and Other Infections [Internet]. [cited 2024 Apr 16]. Available from: https:\/\/actgnetwork.org\/."},{"key":"8973_CR42","unstructured":"ClinicalTrials.gov. Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) [Internet]. [cited 2024 Apr 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06192160."},{"issue":"1","key":"8973_CR43","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1038\/s41467-021-22833-6","volume":"12","author":"ND Walter","year":"2021","unstructured":"Walter ND, Born SE, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, et al. Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. Nat Commun. 2021;12(1):2899.","journal-title":"Nat Commun"},{"key":"8973_CR44","unstructured":"Corbin J, Strauss A. Basics of qualitative research: Techniques and procedures for developing grounded theory. Sage publications; 2014."},{"issue":"18","key":"8973_CR45","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021May 6;384(18):1705\u201318.","journal-title":"N Engl J Med"},{"key":"8973_CR46","unstructured":"International Conference on Harmonisation (ICH). Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Statistical Principles for Clinical Trials E9 (R1) [Internet]. 2019 [cited 2024 Apr 16]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf."},{"issue":"3","key":"8973_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/17407745221080463","volume":"19","author":"M Kang","year":"2022","unstructured":"Kang M, Kendall MA, Ribaudo H, Tierney C, Zheng L, Smeaton L, et al. Incorporating estimands into clinical trial statistical analysis plans. Clin Trials. 2022Jun;19(3):285\u201391.","journal-title":"Clin Trials"},{"key":"8973_CR48","unstructured":"Division of AIDS (DAIDS). Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events [Internet]. 2017 [cited 2024 Apr 16]. Available from: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf."},{"key":"8973_CR49","unstructured":"Manual for Expedited Reporting of Adverse Events to DAIDS [Internet]. [cited 2024 Jul 9]. Available from: https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/manual-expedited-reporting-adverse-events-daids."},{"key":"8973_CR50","unstructured":"WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment - Drug-resistant tuberculosis treatment [Internet]. 2022 [cited 2024 Jul 23]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240063129."},{"issue":"10","key":"8973_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01794-20","volume":"65","author":"AD Gewitz","year":"2021","unstructured":"Gewitz AD, Solans BP, Mac Kenzie WR, Heilig C, Whitworth WC, Johnson JL, et al. Longitudinal model-based biomarker analysis of exposure-response relationships in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2021;65(10):10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"key":"8973_CR52","unstructured":"ClinicalTrials.gov. Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis [Internet]. [cited 2024 Jul 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06058299."},{"issue":"2","key":"8973_CR53","doi-asserted-by":"publisher","first-page":"2300165","DOI":"10.1183\/13993003.00165-2023","volume":"62","author":"JP Ernest","year":"2023","unstructured":"Ernest JP, Goh JJN, Strydom N, Wang Q, van Wijk RC, Zhang N, et al. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. Eur Respir J. 2023Aug 1;62(2):2300165.","journal-title":"Eur Respir J"},{"issue":"10","key":"8973_CR54","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","volume":"167","author":"A Jindani","year":"2003","unstructured":"Jindani A, Dor\u00e9 CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med. 2003M;167(10):1348\u201354.","journal-title":"Am J Respir Crit Care Med"},{"key":"8973_CR55","doi-asserted-by":"crossref","unstructured":"Nyang\u2019wa Bern-Thomas, Berry Catherine, Kazounis Emil, Motta Ilaria, Parpieva Nargiza, Tigay Zinaida, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022 Dec 21;387(25):2331\u201343.","DOI":"10.1056\/NEJMoa2117166"},{"issue":"5","key":"8973_CR56","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa2400327","volume":"392","author":"L Guglielmetti","year":"2025","unstructured":"Guglielmetti L, Khan U, Vel\u00e1squez GE, Gouillou M, Abubakirov A, Baudin E, et al. Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis. N Engl J Med. 2025;392(5):468\u201382.","journal-title":"N Engl J Med"},{"key":"8973_CR57","doi-asserted-by":"crossref","unstructured":"Conradie F, Badat T, Poswa A, Rajaram S, Kooverjee S, Maartens G, et al. BEAT Tuberculosis: a randomized controlled trial of a 6-month strategy for rifampicin-resistant tuberculosis. medRxiv. 2025;2025\u201305.","DOI":"10.1101\/2025.05.04.25326549"},{"issue":"2","key":"8973_CR58","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/S2214-109X(15)00285-5","volume":"4","author":"J Andrews","year":"2016","unstructured":"Andrews J. To be or not to be exclusive: the sutezolid story. Lancet Glob Health. 2016Feb 1;4(2):e89\u201390.","journal-title":"Lancet Glob Health"},{"key":"8973_CR59","doi-asserted-by":"crossref","unstructured":"Sarathy Jansy P, Xie Min, Jones Richard M., Chang Adrienne, Osiecki Paulina, Weiner Danielle, et al. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum. mBio. 2023 Apr 5;14(2):e00598\u201323.","DOI":"10.1128\/mbio.00598-23"},{"issue":"3","key":"8973_CR60","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1128\/AAC.01297-10","volume":"55","author":"JWC Alffenaar","year":"2011","unstructured":"Alffenaar JWC, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de Neeling H, et al. Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480. Antimicrob Agents Chemother. 2011Feb 24;55(3):1287\u20139.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08973-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08973-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08973-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:40:04Z","timestamp":1757428804000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08973-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8973"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08973-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"291"}}